Study results finding that gastrointestinal cancer was the most common other primary systemic cancer in patients with melanoma was the most read-article of the past week on Healio.com/Dermatology.
MRV Research
T-VEC Plus Pembrolizumab Combo Shows Activity in Advanced Melanoma
The combination of the attenuated oncolytic virus talimogene laherparepvec (T-VEC) and the immune checkpoint inhibitor pembrolizumab shows activity and is well tolerated by advanced melanoma patients, according to a new study presented at the Society for Melanoma Research 2015 International Congress, held November 18–21 in San Francisco.
Three-drug nanoparticle cuts back resistance in metastatic melanoma
Researchers at Oregon State University have combined three cancer drugs in a nanoparticle system to treat deadly metastatic skin cancers by targeting the lymph nodes.
In animal tests, the nanoparticle treatment significantly reduced the number of melanoma cells, which are prone to resistance when it comes to normal chemotherapy regimens. The nanoparticles, according to the university, allow the lymph nodes protection from system toxicity while at the same time discouraging drug resistance by carrying three of the drugs at a time.
Scientists identify promising new melanoma drug
A new drug discovered by scientists at Sanford Burnham Prebys Medical Discovery Institute (SBP) may show promise for treating skin cancers that are resistant or unresponsive to today’s leading therapies.
In the United States, 5 million people are treated annually for skin cancer, and 9,000 people die from the deadliest form—melanoma—according to the US Department of Health and Human Services.